Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.

Bianchini D, Omlin A, Pezaro C, Lorente D, Ferraldeschi R, Mukherji D, Crespo M, Figueiredo I, Miranda S, Riisnaes R, Zivi A, Buchbinder A, Rathkopf DE, Attard G, Scher HI, de Bono J, Danila DC.

Br J Cancer. 2013 Nov 12;109(10):2579-86. doi: 10.1038/bjc.2013.619. Epub 2013 Oct 29.

PMID:
24169353
[PubMed - indexed for MEDLINE]
2.

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.

Zhang Y, Castaneda S, Dumble M, Wang M, Mileski M, Qu Z, Kim S, Shi V, Kraft P, Gao Y, Pak J, Sapra P, Bandaru R, Zhao H, Vessella RL, Horak ID, Greenberger LM.

Mol Cancer Ther. 2011 Dec;10(12):2309-19. doi: 10.1158/1535-7163.MCT-11-0329. Epub 2011 Oct 25.

PMID:
22027692
[PubMed - indexed for MEDLINE]
Free Article
3.

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, Sawyers CL, Scher HI.

J Clin Oncol. 2013 Oct 1;31(28):3525-30. doi: 10.1200/JCO.2013.50.1684. Epub 2013 Sep 3.

PMID:
24002508
[PubMed - indexed for MEDLINE]
4.

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.

Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14.

PMID:
20398925
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ.

J Clin Oncol. 2010 Mar 20;28(9):1481-8. doi: 10.1200/JCO.2009.24.1281. Epub 2010 Feb 16.

PMID:
20159824
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Genomic strategy for targeting therapy in castration-resistant prostate cancer.

Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG.

J Clin Oncol. 2009 Apr 20;27(12):2022-9. doi: 10.1200/JCO.2008.17.2882. Epub 2009 Mar 16.

PMID:
19289629
[PubMed - indexed for MEDLINE]
7.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.

PMID:
20823238
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR.

J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.

PMID:
20644256
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR.

PLoS One. 2011;6(11):e27970. doi: 10.1371/journal.pone.0027970. Epub 2011 Nov 17.

PMID:
22114732
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

New hormonal therapies for castration-resistant prostate cancer.

Mostaghel EA, Plymate S.

Endocrinol Metab Clin North Am. 2011 Sep;40(3):625-42, x. doi: 10.1016/j.ecl.2011.05.013. Epub 2011 Jul 14. Review.

PMID:
21889725
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.

Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikström P.

PLoS One. 2011 Apr 28;6(4):e19059. doi: 10.1371/journal.pone.0019059.

PMID:
21552559
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Enzalutamide for the treatment of castration-resistant prostate cancer.

Ha YS, Goodin S, DiPaola RS, Kim IY.

Drugs Today (Barc). 2013 Jan;49(1):7-13. doi: 10.1358/dot.2013.49.1.1910724. Review.

PMID:
23362491
[PubMed - indexed for MEDLINE]
13.

Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG, Vinall R, Tepper CG, Gandour-Edwards R, Shi X, Lu XH, Siddiqui J, Chinnaiyan AM, Mehra R, Devere White RW, Carraway KL 3rd, Ghosh PM.

Cancer Res. 2010 Jul 15;70(14):5994-6003. doi: 10.1158/0008-5472.CAN-09-4440. Epub 2010 Jun 29.

PMID:
20587519
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.

Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, Lee Y, Webb IJ, Scher HI.

J Clin Oncol. 2008 May 1;26(13):2147-54. doi: 10.1200/JCO.2007.15.0532. Epub 2008 Mar 24.

PMID:
18362364
[PubMed - indexed for MEDLINE]
15.

Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.

Mellado B, Marin Aguilera M, Pereira MV.

Arch Esp Urol. 2013 Jun;66(5):453-62. Review.

PMID:
23793763
[PubMed - indexed for MEDLINE]
16.

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.

Cancer Res. 2013 Jan 15;73(2):483-9. doi: 10.1158/0008-5472.CAN-12-3630. Epub 2012 Nov 1.

PMID:
23117885
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.

Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME.

Clin Chem. 2010 Sep;56(9):1492-5. doi: 10.1373/clinchem.2010.143297. Epub 2010 Jun 25.

PMID:
20581083
[PubMed - indexed for MEDLINE]
Free Article
18.

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.

Jeong W, Rapisarda A, Park SR, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S.

Cancer Chemother Pharmacol. 2014 Feb;73(2):343-8. doi: 10.1007/s00280-013-2362-z. Epub 2013 Nov 30.

PMID:
24292632
[PubMed - indexed for MEDLINE]
19.

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7. doi: 10.1073/pnas.1308587110. Epub 2013 Oct 7.

PMID:
24101480
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.

Shiota M, Yokomizo A, Naito S.

J Mol Endocrinol. 2011 Jul 12;47(1):R25-41. doi: 10.1530/JME-11-0018. Print 2011 Aug. Review.

PMID:
21504942
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk